TD Cowen analysts raised the price target on Insmed (NASDAQ:) to $67.00 (from $45.00) while maintaining a Buy rating.
The analysts commented, “We think this AM’s best case scenario ASPEN data drives 80%+ probability of US, EU and JP approval. Given the clinically meaningful effect size with strong stat significance, along with strong stats and/or trends in key secondary endpoints (particularly FEV1 and QoL-B), we predict clean approval and model $3.4B in peak sales using a $30K gross price at launch, and 40% peak market share.”
